10-K: HeartBeam Inc. Reports 2024 Annual Results, Highlights FDA Clearance and Ongoing Development

HeartBeam Inc. announces its 2024 financial results, highlighting FDA clearance for its HeartBeam System and continued progress in developing its ambulatory cardiac monitoring solutions.

Summary

• HeartBeam Inc., a medical technology company, released its 2024 annual report, focusing on transforming cardiac care through personalized insights.
• The company's aim is to deliver innovative ambulatory cardiac monitoring solutions for detecting and monitoring cardiac disease outside healthcare facilities.
• HeartBeam's technology platform collects electrical activity from three directions to synthesize a 12-Lead ECG, showing comparable diagnostic capability to traditional systems.
• The HeartBeam System received FDA clearance on December 13, 2024, marking it as the first cable-free, ambulatory ECG capturing signals from three directions.
• In January 2025, HeartBeam filed a 510(k) notification for software algorithms synthesizing a 12L ECG from the HeartBeam System.
• This submission is supported by data from the VALID-ECG study, which enrolled 198 patients across five clinical sites.
• The company is initiating an Early Access Program for the HeartBeam System to gather user feedback and prepare for commercialization.
• HeartBeam has an active AI program, having acquired approximately one million 12L ECGs and developed deep learning algorithms for detecting cardiac arrhythmias.
• The company holds 14 issued U.S. patents and nine pending U.S. applications, with patents predicted to expire between April 11, 2036, and April 21, 2042.
• The Connected Medical Device Market is estimated at $66 billion in 2024 and is expected to reach $133 billion by 2029, growing at a CAGR of 15%.
• The market for cardiac monitoring technologies is projected to reach approximately $18 billion by 2030, a CAGR of approximately 8%.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the FDA clearance and technological advancements are positive, the financial losses, going concern warning, and need for additional capital raise concerns.

Positives

• FDA clearance for the HeartBeam System provides a regulatory foundation for subsequent products.
• The VALID-ECG study supports the clinical equivalence of HeartBeam's synthesized 12-lead ECG.
• The Early Access Program will provide valuable feedback on the user experience and workflow of the system.
• The AI program and acquisition of 12L ECGs will enhance diagnostic capabilities.
• The company holds a significant intellectual property portfolio with 14 issued U.S. patents.

Negatives

• The company does not anticipate significant revenue from the HeartBeam System clearance before the clearance of the synthesized 12L algorithm.
• The company has incurred losses each year since inception and has experienced negative cash flows from operations in each year since inception.
• The company's auditors have issued a going concern opinion on the December 31, 2024 financial statements, expressing substantial doubt that the company can continue as an ongoing business for the next twelve months.

Risks

• The company requires additional capital to support its business plan, and such capital may not be available on acceptable terms.
• The company has a limited operating history upon which investors can evaluate its future prospects.
• Management and the independent registered public accounting firm have expressed substantial doubt about the company's ability to continue as a going concern.
• The company may never complete the development and commercialization of products that it is currently developing.
• The company's business is dependent upon physicians utilizing and prescribing its solution; if the company fails to engage physicians to utilize its solution, its revenues may never materialize or may not meet its projections.
• The company is subject to extensive governmental regulations relating to the manufacturing, labeling, and marketing of its products.
• If the company is not able to both obtain and maintain adequate levels of third-party reimbursement for its products, it would have a material adverse effect on its business.
• Product defects could adversely affect the results of the company's operations.
• Interruptions or delays in telecommunications systems or in the data services provided to the company by cellular communication providers or the loss of its wireless or data services could impair the delivery of its cardiac monitoring services.
• Interruptions in computing and data management cloud systems could impair the delivery of the company's cardiac monitoring services.
• The company could be exposed to significant liability claims if it is unable to obtain insurance at acceptable costs and adequate levels or otherwise protect itself against potential product liability claims.
• The results of the company's research and development efforts are uncertain and there can be no assurance of the commercial success of its products.
• If the company fails to retain certain of its key personnel and attract and retain additional qualified personnel, it might not be able to pursue its growth strategy.
• The company will not be profitable unless it can demonstrate that its products can be manufactured at low prices.
• If the company or its suppliers fail to achieve or maintain regulatory approval of manufacturing facilities, its growth could be limited and its business could be harmed.
• The company's dependence on a limited number of suppliers may prevent it from delivering its devices on a timely basis.
• The company relies significantly on information technology and any failure, inadequacy, or security lapse of that technology, including any cybersecurity incidents, could harm it.
• The company cannot provide assurances that in the future there will be no weaknesses in its internal controls and that they will be effectively remediated if any were to occur in the future.
• The company maintains its cash at financial institutions, often in balances that exceed federally insured limits.
• Changes in tax laws or regulations may increase tax uncertainty and adversely affect results of the company's operations and its effective tax rate.
• Escalating global trade tensions, the Russia and Ukraine war, the Israel-Hamas war, the adoption or expansion of tariffs and trade restrictions and economic disruption and uncertainty resulting therefrom could negatively impact the company.
• Natural disasters and other events beyond the company's control could materially adversely affect it.
• The company may face risks related to health epidemics and pandemics or other outbreaks of communicable diseases.
• The industry in which the company operates is highly competitive and subject to rapid technological change.
• Unsuccessful clinical trials or procedures relating to products under development could have a material adverse effect on the company's prospects.
• Intellectual property litigation and infringement claims could cause the company to incur significant expenses or prevent it from selling certain of its products.
• If the company is unable to protect the confidentiality of its trade secrets, its business and competitive position would be harmed.
• If the company is unable to protect its proprietary rights, or if it infringes on the proprietary rights of others, its competitiveness and business prospects may be materially damaged.
• Dependence on the company's proprietary rights and failing to protect such rights or to be successful in litigation related to such rights may result in its payment of significant monetary damages or impact offerings in its product portfolios.
• Enforcement of federal and state laws regarding privacy and security of patient information may adversely affect the company's business, financial condition or operations.
• The company may become subject, directly or indirectly, to federal and state health care fraud and abuse laws and regulations and if it is unable to fully comply with such laws, the company could face substantial penalties.
• The company may be subject to federal and state false claims laws which impose substantial penalties.
• The price of the company's Common Stock and Warrants may be subject to wide fluctuations.
• The company is an emerging growth company, and any decision on its part to comply with certain reduced disclosure requirements.
• The company is a smaller reporting company, and it cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make its common stock less attractive to investors.
• Future sales and issuances of the company's Common Stock or rights to purchase Common Stock, including pursuant to its equity incentive plans and other equity securities could result in dilution of the percentage ownership of its stockholders and could cause its stock price to fall.
• Nasdaq Capital Market, may delist the company's Common Stock if it fails to comply with ongoing listing standards.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about the company's business, its stock price and trading volume could decline.
• The company's need for future financing may result in the issuance of additional securities which will cause investors to experience dilution.
• If the company's shares become subject to the penny stock rules, it would become more difficult to trade its shares.
• Liability of directors for breach of duty is limited under Delaware law.
• The company does not anticipate paying any cash dividends on its Common Stock in the foreseeable future and, as such, capital appreciation, if any, of its Common Stock will be your sole source of gain for the foreseeable future.

Future Outlook

The company plans to continue developing its synthesized 12L technology and AI-based cardiac disease detection algorithms. They also plan to expand solutions that diagnose all major cardiac conditions that are diagnosed by ECGs.

Management Comments

• Management believes the continued achievement of milestones will provide the Company the ability to raise additional capital.

Industry Context

The company operates in the rapidly growing field of ambulatory cardiac health monitoring, which is driven by the increasing prevalence of cardiovascular disease and the need for cost-effective diagnostic solutions. The Connected Medical Device Market is estimated at $66 billion in 2024 and is expected to reach $133 billion by 2029, growing at a CAGR of 15%.

Comparison to Industry Standards

• The HeartBeam System competes with ambulatory cardiac monitors, including consumer devices like the Apple Watch and AliveCor's KardiaMobile, which primarily focus on arrhythmia detection.
• It also competes with devices prescribed for ischemia detection, such as Avertix Medical's AngelMed Guardian and SHL Telemedicine's Smartheart.
• The company believes its technology will address market needs and has several key attributes that make it a good fit for these patients.
• The company believes its ECG platform will demonstrate 12L equivalence and clinical and cost-effectiveness advantages, coupled with a patent protected technology, we believe this might open multiple licensing and/or partnering opportunities with players in the ECG, cardiac monitoring patch and smart watch verticals.

Management Changes

Related Party Transactions

• During April 2024, the Company entered into consulting agreement with one of the independent Board of Directors to provide business development consulting services.
• For these consulting services, the Company agreed to pay $5,000 per month as remuneration and granted 70,000 options to vest during over a period of 36 months.
• During year ended December 31, 2024, the Company recognized approximately $75,800 related to these consulting services, which includes stock based compensation expense of approximately $30,800.

Stakeholder Impact

• Shareholders face potential dilution from future stock issuances.
• Employees may be affected by potential cost-cutting measures or changes in compensation.
• Patients could benefit from the development of innovative cardiac monitoring solutions.
• Healthcare providers may have access to more accurate and convenient diagnostic tools.
• Suppliers and creditors face potential risks related to the company's financial stability.

Next Steps

• Continue with the Early Access Program for the HeartBeam System.
• Pursue FDA clearance for the 12L synthesis algorithm.
• Continue development of AI-based cardiac disease detection algorithms.
• Refine go-to-market strategy and engage with industry players.
• Continue to seek additional financing.

Key Dates